Silvan Turkcan

Stock Analyst at Citizens

(2.35)

# 2,587

Out of 5,152 analysts

Total ratings

100%

Success rate

17.2%

Average return

Main Sectors:

Top Industries:

Stocks Rated by Silvan Turkcan

	Stock	Action	Price Target	Current	Upside	Ratings	Updated
	NTLA Intellia Therapeutics	Maintains: Market Outperform	$21 → $28	$13.82	+102.60%	1	Mar 3, 2026
	CRSP CRISPR Therapeutics AG	Maintains: Market Outperform	$86 → $80	$60.00	+33.33%	1	Jan 30, 2026

Intellia Therapeutics

Mar 3, 2026

Maintains: Market Outperform

Price Target: $21 → $28

Current: $13.82

Upside: +102.60%

CRISPR Therapeutics AG

Jan 30, 2026

Maintains: Market Outperform

Price Target: $86 → $80

Current: $60.00

Upside: +33.33%